Zengjun Li

2.1k total citations
132 papers, 1.2k citations indexed

About

Zengjun Li is a scholar working on Pathology and Forensic Medicine, Molecular Biology and Genetics. According to data from OpenAlex, Zengjun Li has authored 132 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 54 papers in Pathology and Forensic Medicine, 46 papers in Molecular Biology and 46 papers in Genetics. Recurrent topics in Zengjun Li's work include Lymphoma Diagnosis and Treatment (48 papers), Chronic Lymphocytic Leukemia Research (43 papers) and Multiple Myeloma Research and Treatments (18 papers). Zengjun Li is often cited by papers focused on Lymphoma Diagnosis and Treatment (48 papers), Chronic Lymphocytic Leukemia Research (43 papers) and Multiple Myeloma Research and Treatments (18 papers). Zengjun Li collaborates with scholars based in China, United States and United Kingdom. Zengjun Li's co-authors include Yanlai Sun, Jianjun Han, Zhongfa Xu, Shuhua Yi, Dehui Zou, Lugui Qiu, Huirong Xu, Yan Xu, Jianning Li and Weiwei Sui and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Zengjun Li

115 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Zengjun Li China 19 489 478 301 251 246 132 1.2k
Hyeon Seok Eom South Korea 15 392 0.8× 590 1.2× 671 2.2× 180 0.7× 136 0.6× 58 1.3k
Rodney R. Miles United States 19 613 1.3× 491 1.0× 460 1.5× 163 0.6× 179 0.7× 68 1.4k
Claire Seedhouse United Kingdom 25 1.1k 2.3× 548 1.1× 152 0.5× 158 0.6× 246 1.0× 62 1.7k
Yin‐Hsun Feng Taiwan 20 732 1.5× 475 1.0× 127 0.4× 74 0.3× 476 1.9× 69 1.5k
Xiaorui Fu China 19 360 0.7× 605 1.3× 639 2.1× 125 0.5× 224 0.9× 91 1.2k
Benjamin D. Hedley Canada 16 464 0.9× 544 1.1× 104 0.3× 93 0.4× 228 0.9× 40 1.1k
Steven Novick United States 16 819 1.7× 437 0.9× 178 0.6× 362 1.4× 79 0.3× 28 1.4k
Fangfang Lv China 14 215 0.4× 432 0.9× 275 0.9× 139 0.6× 133 0.5× 65 840
Keigo Yorozu United States 18 285 0.6× 566 1.2× 98 0.3× 91 0.4× 89 0.4× 52 1.0k
Gennaro Gadaleta‐Caldarola Italy 19 312 0.6× 406 0.8× 129 0.4× 43 0.2× 189 0.8× 51 1.0k

Countries citing papers authored by Zengjun Li

Since Specialization
Citations

This map shows the geographic impact of Zengjun Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zengjun Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zengjun Li more than expected).

Fields of papers citing papers by Zengjun Li

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Zengjun Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zengjun Li. The network helps show where Zengjun Li may publish in the future.

Co-authorship network of co-authors of Zengjun Li

This figure shows the co-authorship network connecting the top 25 collaborators of Zengjun Li. A scholar is included among the top collaborators of Zengjun Li based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Zengjun Li. Zengjun Li is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Xia, Yin, Dan Liu, Hui Wang, et al.. (2025). Zanubrutinib plus R‐CHOP for the treatment of newly diagnosed double‐expressor lymphoma: A phase 2 clinical study. Cancer. 131(1). e35697–e35697. 2 indexed citations
2.
3.
4.
Ma, Jun, Huiqiang Huang, Peifen Fu, et al.. (2021). Prophylaxis of neutropenia with mecapegfilgrastim in patients with non-myeloid malignancies: a real-world study. Annals of Translational Medicine. 9(10). 893–893. 2 indexed citations
5.
Sun, Yanlai, Zhen Cao, Yang Gao, et al.. (2021). Hsa_circ_0020095 Promotes Oncogenesis and Cisplatin Resistance in Colon Cancer by Sponging miR-487a-3p and Modulating SOX9. Frontiers in Cell and Developmental Biology. 8. 604869–604869. 22 indexed citations
6.
Ma, Dejian, Zengjun Li, Xiyan Wang, Xianjun Zhu, & Yanlai Sun. (2019). Octreotide treatment of cancer chemoradiotherapy-induced diarrhoea: a meta-analysis of randomized controlled trials. Translational Cancer Research. 8(6). 2284–2294.
7.
Ma, Dejian, et al.. (2018). c.1439delA frameshift deletion mutation in familial adenomatous polyposis. OncoTargets and Therapy. Volume 11. 8987–8993.
8.
Li, Heng, Shuhua Yi, Wenjie Xiong, et al.. (2017). Chronic Lymphocytic Leukemia Prognostic Index: A New Integrated Scoring System to Predict the Time to First Treatment in Chinese Patients with Chronic Lymphocytic Leukemia.. SHILAP Revista de lepidopterología. 130(2). 135–142. 5 indexed citations
9.
Yin, Lei, Chunhong Zhao, Zengjun Li, et al.. (2017). Antitumor effects of oncolytic herpes simplex virus type 2 against colorectal cancer in vitro and in vivo. Therapeutics and Clinical Risk Management. Volume 13. 117–130. 14 indexed citations
10.
Li, Cheng, Zhongfa Xu, Yingming Wang, et al.. (2017). Robot-assisted versus conventional laparoscopic operation in anus-preserving rectal cancer: a meta-analysis. Therapeutics and Clinical Risk Management. Volume 13. 1247–1257. 25 indexed citations
11.
Chen, Weiyan, et al.. (2016). Elevated Levels of Protein Disulfide Isomerase and Binding Immunoglobulin Protein Implicated in Spinal Cord Injury Paraplegia Patients with Pressure Ulcers. Genetic Testing and Molecular Biomarkers. 20(7). 367–372. 1 indexed citations
12.
Yi, Shuhua, Zengjun Li, Dehui Zou, et al.. (2016). Intratumoral genetic heterogeneity and number of cytogenetic aberrations provide additional prognostic significance in chronic lymphocytic leukemia. Genetics in Medicine. 19(2). 182–191. 13 indexed citations
13.
14.
Hao, Mu, Meirong Zang, Yan Xu, et al.. (2015). Serum High Expression of Micorna-214 Is a Novel Predictor for Myeloma Bone Disease and Poor Prognosis. Blood. 126(23). 4186–4186. 2 indexed citations
15.
Xu, Zhongfa, Zengjun Li, Yanlai Sun, et al.. (2015). A Novel Spherical Magnetic Compression Device for Colorectal Anastomosis in a Swine Model. Journal of Laparoendoscopic & Advanced Surgical Techniques. 25(4). 323–329. 3 indexed citations
16.
Li, Zengjun, Yan Xu, Gang An, et al.. (2015). [The characteristics of 62 cases of CD20-positive multiple myeloma].. PubMed Central. 36(1). 44–8. 3 indexed citations
17.
Li, Fei, Mu Hao, Xiaoyan Feng, et al.. (2015). Downregulated miR-33b is a novel predictor associated with disease progression and poor prognosis in multiple myeloma. Leukemia Research. 39(7). 793–799. 22 indexed citations
18.
Zang, Meirong, Zengjun Li, Lanting Liu, et al.. (2015). Anti-tumor activity of the proteasome inhibitor BSc2118 against human multiple myeloma. Cancer Letters. 366(2). 173–181. 7 indexed citations
19.
Yi, Shuhua, Rui Cui, Zengjun Li, et al.. (2014). Distinct characteristics and new prognostic scoring system for Chinese patients with Waldenström macroglobulinemia. Chinese Medical Journal. 127(12). 2327–2331. 4 indexed citations
20.
Xu, Huirong, Jianning Li, Yanlai Sun, et al.. (2014). Robotic versus laparoscopic right colectomy: a meta-analysis. World Journal of Surgical Oncology. 12(1). 274–274. 54 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hyeon Seok Eom Breakdown of academic impact, for papers by Rodney R. Miles Breakdown of academic impact, for papers by Claire Seedhouse Breakdown of academic impact, for papers by Yin‐Hsun Feng Breakdown of academic impact, for papers by Xiaorui Fu Breakdown of academic impact, for papers by Benjamin D. Hedley Breakdown of academic impact, for papers by Steven Novick Breakdown of academic impact, for papers by Fangfang Lv Breakdown of academic impact, for papers by Keigo Yorozu Breakdown of academic impact, for papers by Gennaro Gadaleta‐Caldarola
Rankless by CCL
2026